Law360, New York (June 24, 2014, 2:48 PM EDT) -- GlaxoSmithKline PLC failed to take appropriate steps to prevent bacterial contamination of its widely used flu vaccine Flulaval, causing many product batches to become tainted, according to a U.S. Food and Drug Administration warning letter released Tuesday.
The FDA’s letter, which stems from inspections in March and April, describes quality control processes at a GSK plant in Canada that had several loopholes and were applied inconsistently, resulting in microbial contamination that forced drug lots to be discarded.
For example, GSK did not have comprehensive written policies to prevent contamination of purportedly sterile products, and to the extent that policies were in...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!